BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 15152938)

  • 1. Structure-activity analysis of taxane-based broad-spectrum multidrug resistance modulators.
    Brooks TA; Kennedy DR; Gruol DJ; Ojima I; Baer MR; Bernacki RJ
    Anticancer Res; 2004; 24(2A):409-15. PubMed ID: 15152938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein.
    Brooks TA; Minderman H; O'Loughlin KL; Pera P; Ojima I; Baer MR; Bernacki RJ
    Mol Cancer Ther; 2003 Nov; 2(11):1195-205. PubMed ID: 14617793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Broad-spectrum modulation of ATP-binding cassette transport proteins by the taxane derivatives ortataxel (IDN-5109, BAY 59-8862) and tRA96023.
    Minderman H; Brooks TA; O'Loughlin KL; Ojima I; Bernacki RJ; Baer MR
    Cancer Chemother Pharmacol; 2004 May; 53(5):363-9. PubMed ID: 15060738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclosporin A is a broad-spectrum multidrug resistance modulator.
    Qadir M; O'Loughlin KL; Fricke SM; Williamson NA; Greco WR; Minderman H; Baer MR
    Clin Cancer Res; 2005 Mar; 11(6):2320-6. PubMed ID: 15788683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. VX-710 (biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein.
    Minderman H; O'Loughlin KL; Pendyala L; Baer MR
    Clin Cancer Res; 2004 Mar; 10(5):1826-34. PubMed ID: 15014037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro and in vivo evaluation of WK-X-34, a novel inhibitor of P-glycoprotein and BCRP, using radio imaging techniques.
    Jekerle V; Klinkhammer W; Scollard DA; Breitbach K; Reilly RM; Piquette-Miller M; Wiese M
    Int J Cancer; 2006 Jul; 119(2):414-22. PubMed ID: 16646006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of P-glycoprotein but not MRP1- or BCRP-mediated drug resistance by LY335979.
    Shepard RL; Cao J; Starling JJ; Dantzig AH
    Int J Cancer; 2003 Jan; 103(1):121-5. PubMed ID: 12455064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel tetrahydroisoquinolin-ethyl-phenylamine based multidrug resistance inhibitors with broad-spectrum modulating properties.
    Jekerle V; Klinkhammer W; Reilly RM; Piquette-Miller M; Wiese M
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):61-9. PubMed ID: 16636798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The 4'-O-benzylated doxorubicin analog WP744 overcomes resistance mediated by P-glycoprotein, multidrug resistance protein and breast cancer resistance protein in cell lines and acute myeloid leukemia cells.
    Brooks TA; O'Loughlin KL; Minderman H; Bundy BN; Ford LA; Vredenburg MR; Bernacki RJ; Priebe W; Baer MR
    Invest New Drugs; 2007 Apr; 25(2):115-22. PubMed ID: 17072745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis and structure-activity relationships of novel taxane-based multidrug resistance reversal agents.
    Ojima I; Borella CP; Wu X; Bounaud PY; Oderda CF; Sturm M; Miller ML; Chakravarty S; Chen J; Huang Q; Pera P; Brooks TA; Baer MR; Bernacki RJ
    J Med Chem; 2005 Mar; 48(6):2218-28. PubMed ID: 15771464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2).
    Doyle L; Ross DD
    Oncogene; 2003 Oct; 22(47):7340-58. PubMed ID: 14576842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel microtubule-targeting agents, pyrrolo-1,5-benzoxazepines, induce apoptosis in multi-drug-resistant cancer cells.
    Nathwani SM; Butler S; Fayne D; McGovern NN; Sarkadi B; Meegan MJ; Lloyd DG; Campiani G; Lawler M; Williams DC; Zisterer DM
    Cancer Chemother Pharmacol; 2010 Aug; 66(3):585-96. PubMed ID: 20020128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of ABC-cassette transporters (MDR1, MRP1, BCRP) in the development of primary and acquired multiple drug resistance in patients with early and metastatic breast cancer.
    Kovalev AA; Tsvetaeva DA; Grudinskaja TV
    Exp Oncol; 2013 Dec; 35(4):287-90. PubMed ID: 24382439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversal of P-gp and BCRP-mediated MDR by tariquidar derivatives.
    Li XQ; Wang L; Lei Y; Hu T; Zhang FL; Cho CH; To KK
    Eur J Med Chem; 2015 Aug; 101():560-72. PubMed ID: 26197160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2).
    Shen H; Lee FY; Gan J
    J Pharmacol Exp Ther; 2011 May; 337(2):423-32. PubMed ID: 21262849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Arylamino Esters As P-Glycoprotein Modulators: SAR Studies to Establish Requirements for Potency and Selectivity.
    Teodori E; Dei S; Floriddia E; Perrone MG; Manetti D; Romanelli MN; Contino M; Colabufo NA
    ChemMedChem; 2015 Aug; 10(8):1339-43. PubMed ID: 26012726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel structure-activity relationships and selectivity profiling of cage dimeric 1,4-dihydropyridines as multidrug resistance (MDR) modulators.
    Coburger C; Wollmann J; Krug M; Baumert C; Seifert M; Molnár J; Lage H; Hilgeroth A
    Bioorg Med Chem; 2010 Jul; 18(14):4983-90. PubMed ID: 20598550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Function of the ABC transporters, P-glycoprotein, multidrug resistance protein and breast cancer resistance protein, in minimal residual disease in acute myeloid leukemia.
    van der Pol MA; Broxterman HJ; Pater JM; Feller N; van der Maas M; Weijers GW; Scheffer GL; Allen JD; Scheper RJ; van Loevezijn A; Ossenkoppele GJ; Schuurhuis GJ
    Haematologica; 2003 Feb; 88(2):134-47. PubMed ID: 12604403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zafirlukast antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance.
    Sun YL; Kathawala RJ; Singh S; Zheng K; Talele TT; Jiang WQ; Chen ZS
    Anticancer Drugs; 2012 Sep; 23(8):865-73. PubMed ID: 22614107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HM30181 Derivatives as Novel Potent and Selective Inhibitors of the Breast Cancer Resistance Protein (BCRP/ABCG2).
    Köhler SC; Wiese M
    J Med Chem; 2015 May; 58(9):3910-21. PubMed ID: 25855895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.